5β-pregnan-3β, 20α-diol | 38270-97-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5β-pregnan-3β, 20α-diol
• 英文别名: (3S,5R,8R,9S,10S,13S,14S,17S)-17-(1-hydroxyethyl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 38270-97-2
• 化学式: C₂₁H₃₆O₂
• 分子量: 320.516
• InChiKey: YWYQTGBBEZQBGO-YMQZRTQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Pregnane steroids for use in the treatment of cns disorders
  申请人：Backstrom Torbjorn

  公开号：US20050222099A1

  公开（公告）日：2005-10-06

  Steroid compounds prossessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.

  在 3beta 位具有氢供体的类固醇化合物，无论是以羟基还是硫酸基的形式，都能有效阻断 3α-羟基-孕甾醇的作用，因此可用作预防和/或治疗与类固醇有关的中枢神经系统疾病的治疗物质。已公开了基于这些物质的治疗方法，还建议将这些物质单独或组合用于制造治疗许多特定类固醇引起的中枢神经系统疾病的药物。
• PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS
  申请人：Umecrine AB

  公开号：EP1458399A1

  公开（公告）日：2004-09-22
• GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
  申请人：Umecrine AB

  公开号：EP1812009B1

  公开（公告）日：2013-05-15
• Pregnane steroids for use in the treatment of CNS disorders
  申请人：Umecrine AB

  公开号：EP2275109B1

  公开（公告）日：2013-07-24
• PREGNANE STEROIDS AND THEIR USE IN THE TREATMENT OF CNS DISORDERS
  申请人：Backstrom Torbjorn

  公开号：US20110098259A1

  公开（公告）日：2011-04-28

  Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.